欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (12): 1429-1435.doi: 10.12092/j.issn.1009-2501.2020.12.016

• 综述与讲座 • 上一篇    下一篇

偏头痛药物预防及治疗新进展

杨心怡,张菁,李南洋,杨海静,毛肖萌   

  1. 复旦大学附属华山医院I期临床研究室,上海 200040
  • 收稿日期:2020-08-21 修回日期:2020-10-14 出版日期:2020-12-26 发布日期:2021-01-04
  • 通讯作者: 张菁,女,博士,主任药师,主要从事创新药物I期临床研究。
  • 作者简介:杨心怡,女,硕士,住院医师,主要从事神经药物临床研究。
  • 基金资助:
    “重大新药创制”科技重大专项(“十三五”)(2017ZX09304005)

New progress in drug prevention and treatment of migraine

YANG Xinyi, ZHANG Jing, LI Nanyang, YANG Haijing, MAO Xiaomeng   

  1. Phase I Unit, Huashan Hospital, Fudan University, Shanghai 200040, China
  • Received:2020-08-21 Revised:2020-10-14 Online:2020-12-26 Published:2021-01-04

摘要: 偏头痛是一种常见的神经内科疾病,严重影响生活质量,目前临床上的常用治疗药物尚不能满足临床需求。随着研究的不断深入,5-羟色胺1F受体激动剂、靶向作用于降钙素基因相关肽(CGRP)的药物等越来越多地被研发和上市。本文系统评估这些药物的作用机制、安全性及有效性、代谢特点等,为临床防治偏头痛提供更为科学的依据。 

关键词: 偏头痛, 抗CGRP单克隆抗体, 药代动力学

Abstract: Migraine is a common nervous system disease, which could seriously affect the quality of life. However, the medical treatment of migraine cannot meet the clinical needs at present. With the deepening of research, serotonin 1F receptor agonists and drugs targeting CGRP are more and more developed and marketed. In this paper, the mechanism of action, safety and efficacy, metabolic characteristics of these drugs were systematically evaluated to provide a more scientific basis for clinical prevention and treatment of migraine. 

Key words: migraine, monoclonal antibody against CGRP, pharmacokinetics

中图分类号: